Genenta Science reports preliminary results of Temferon-glioblastoma study

May 24, 2022

Biotech company Genenta Science is developing a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers, according to co-founder Dr. Bernhard Gentner, PhD.

ScienceBoard.net spoke to Gentner at the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington, DC, about Temferon, which is under investigation in a phase I/IIa clinical trial in newly diagnosed glioblastoma multiforme patients.

"We have treated so far 16 patients with this strategy," Gentner said, noting that early results are promising with T cell response activation in some patients. "We did this in glioblastoma patients, which is really a terrible tumor which has no cure today."

Watch the video below to learn more.


How to address challenges in producing AAV vectors
There are challenges in producing sufficient quantities of gene therapy products, particularly when it comes to adeno-associated virus (AAV) vectors,...
Atsena Therapeutics’ gene therapy takes aim at childhood blindness
In an interview with ScienceBoard.net, Patrick Ritschel, CEO of Ophthalmology-based gene therapy company Atsena Therapeutics, shared an overview...
Omega Therapeutics looks to tap 'nature's operating system' to control gene expression
Precision genomic medicine company Omega Therapeutics is looking to harness “nature’s operating system” for controlling gene expression and cell differentiation,...
Delivery of gene therapies remains a key challenge
Gene therapy holds great promise for treating inherited disorders, cancers, and other diseases, but delivery of these therapies remains a key challenge,...
Next evolution of CAR T-cell therapy is solid tumors
While chimeric antigen receptor (CAR) T-cell therapy has become a game changer for some patients with blood cancer, the next area of evolution for the...

Copyright © 2022 scienceboard.net

Last Updated 5/24/2022 7:03:03 AM